Conventional stroke therapies such as thrombolysis and thrombectomy are effective, but they have several limitations. Stem cell therapy is a promising treatment modality that has demonstrated potential in neuroprotection, neuroregeneration, and functional recovery. 

Twenty-six studies including 1140 participants, were analyzed. Pooled results showed that, compared to the control group, stem cell therapy significantly decreased mRS scores  (MD, -0.34; 95%CI [-0.51, -0.17], P=0.00), decreased NIHSS scores (MD, -1.77; 95%CI [-2.28, -1.25]; P=0.00) and increased BI (MD, 6.20; 95%CI [3.46, 8.94], P=0.00). No significant differences were found concerning SAEs and mortality (P=0.52 and P=0.80, respectively). 

Our meta-analysis shows that stem cell therapy improves functional outcomes in ischemic stroke patients by reducing mRS and NIHSS scores, increasing BI scores, and without increased risk of adverse events or mortality. Further large-scale trials are needed to confirm its long-term efficacy and safety.